Evidence map›Paper›PMID 24352453›Full record

ArticleJournal of virology2014

Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions.

Filippos Porichis, Meghan G Hart, Jennifer Zupkosky, Lucie Barblu, Douglas S Kwon, Ashley McMullen, Thomas Brennan, Rafi Ahmed, Gordon J Freeman, Daniel G Kavanagh and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 65 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. The role of CD4MedComm · 2023
    Review
  9. Review
  10. Article
  11. Cellular Senescence in Immunity against Infections.International journal of molecular sciences · 2022
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Filippos PorichisRagon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Meghan G Hart
Jennifer Zupkosky
Lucie Barblu
Douglas S Kwon
Ashley McMullen
Thomas Brennan
Rafi Ahmed
Gordon J Freeman
Daniel G Kavanagh
Daniel E Kaufmann
Harvard University · USRagon Institute of MGH, MIT and Harvard · USEmory University · USMassachusetts General Hospital · US

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI AHMED, RAFI · 2012 to 2018
$131.5M
Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHARPE, ARLENE H. · 2003 to 2023
$42.5M
Targeting the PD-1 signaling pathway to rescue HIV T cell dysfunctionP01AI080192 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI · 2008 to 2012
$12.6M
Visualizing Effects of Costimulation on Antiviral ImmunityP01AI078897 · NIAID · HARVARD MEDICAL SCHOOL · PI VON ANDRIAN, ULRICH H · 2008 to 2012
$12.1M
Immunoregulatory networks and HIV pathogenesisR01HL092565 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI KAUFMANN, DANIEL E · 2007 to 2015
$3.4M
NHLBI NIH HHS R01 HL-092565NHLBI NIH HHS R01 HL092565NIAID NIH HHS AI56299NIAID NIH HHS P01 AI056299NIAID NIH HHS P01 AI078897NIAID NIH HHS P01 AI-080192NIAID NIH HHS P01 AI080192NIAID NIH HHS UM1 AI100663NIAID NIH HHS UM1AI100663
6 · The paper itself

Abstract

unlabelledAntigen persistence in chronic infections and cancer upregulates inhibitory networks, such as the PD-1 and interleukin-10 (IL-10) pathways, that impair immunity and lead to disease progression. These pathways are attractive targets for immunotherapy, as demonstrated by recent clinical trials of PD-1/PD-L1 blockade in cancer patients. However, in HIV-1 infection not all subjects respond to inhibition of either pathway and the mechanistic interactions between these two networks remain to be better defined. Here we demonstrate that in vitro blockade of PD-L1 and/or IL-10Rα results in markedly different profiles of HIV-1-specific CD4 T cell restoration. Whereas PD-L1 blockade leads to balanced increase in gamma interferon (IFN-γ), IL-2, and IL-13 secretion, IL-10Rα blockade preferentially restores IFN-γ production. In viremic subjects, combined PD-L1/IL-10Rα blockade results in a striking 10-fold increase in IFN-γ secretion by HIV-1-specific CD4 T cells that is not observed in subjects with spontaneous (elite controllers) or therapy-induced control of viral replication. In contrast to the dramatic increase in IFN-γ production, concurrent blockade has a marginal additive effect on IL-2 production, IL-13 secretion, and HIV-1-specific CD4 T cell proliferation. IFN-γ produced by Thelper cells upregulates PD-L1, HLA I/II, and IL-12 expression by monocytes. The effect of combined blockade on IFN-γ was dependent on reciprocal reinforcement through IL-12. These studies provide crucial information on the different immunoregulatory qualities of PD-1 and IL-10 in progressive disease and link exhausted virus-specific CD4 T cells and monocytes in the regulation of IFN-γ and IL-12 secretion. IMPORTANCE: Infection with HIV results in most people in uncontrolled viral replication and progressive weakening of the body defenses. In the absence of antiviral therapy, this process results in clinical disease, or AIDS. An important reason why HIV continues to multiply is that a population of white blood cells called CD4 T cells that targets the virus fails to work properly. At least part of this impairment is under the control of inhibitory mechanisms that can be blocked to improve the function of these CD4 T cells. In this report, we show that blocking one or two of the molecules involved, called PD-1 and IL-10, has different effects on the individual functions of these cells and that one is strongly improved. We investigate how these effects are caused by interactions between CD4 T cells and antigen-presenting cells. These observations can have implications for new therapeutic approaches in HIV infection.

Indexed as

Antibodies, MonoclonalAntigen-Presenting CellsB7-H1 AntigenCD4-Positive T-LymphocytesCytokinesEpitopes, T-LymphocyteHIV-1HIV InfectionsHumansInterferon-gammaInterleukin-10Interleukin-10 Receptor alpha SubunitLymphocyte ActivationMonocytesProgrammed Cell Death 1 ReceptorSignal TransductionAntibodies, MonoclonalB7-H1 AntigenCD274 protein, humanCytokinesEpitopes, T-LymphocyteInterferon-gammaInterleukin-10Interleukin-10 Receptor alpha SubunitProgrammed Cell Death 1 Receptor

Identifiers

PMID24352453
PMCPMC3958087
OpenAlexW2140369740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.